Provided by Tiger Trade Technology Pte. Ltd.

IT Tech Packaging Inc

0.2030
+0.00995.13%
Post-market: 0.20550.0025+1.23%19:58 EST
Volume:201.07K
Turnover:40.28K
Market Cap:3.44M
PE:-0.24
High:0.2066
Open:0.1950
Low:0.1950
Close:0.1931
52wk High:1.00
52wk Low:0.1510
Shares:16.97M
Float Shares:16.42M
Volume Ratio:0.61
T/O Rate:1.22%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8619
EPS(LYR):-0.9779
ROE:-6.92%
ROA:-3.36%
PB:0.02
PE(LYR):-0.21

Loading ...

Takeda’s Mezagitamab ITP Extension Study: Long-Term Data That Matters for Investors

TIPRANKS
·
Feb 05

Bionano Announces Publication from Sanford Burnham Prebys Medical Discovery Institute Describing use of OGM to Detect Genomic Alterations Introduced by Gene Editing Technologies

GlobeNewswire
·
Feb 04

CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones

GlobeNewswire
·
Jan 12

Press Release: Bionano Reports Preliminary Fourth Quarter and Full-Year 2025 Results

Dow Jones
·
Jan 12

argenx Highlights 2026 Strategic Priorities

GlobeNewswire
·
Jan 12

Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026

GlobeNewswire
·
Jan 08

Hangzhou's "Six Little Dragons" See Another IPO Emerge

Deep News
·
Jan 05

argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease

GlobeNewswire
·
Dec 15, 2025

Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses

GlobeNewswire
·
Dec 09, 2025

Final 2026 Clinical Lab Fee Schedule Indicates a 47% Increase in Payment Determination for the Category I CPT Code for OGM use in Hematologic Malignancies

GlobeNewswire
·
Dec 03, 2025

Novartis data underscore pioneering scientific innovation in Hematology and Oncology at ASH and SABCS

GlobeNewswire
·
Nov 25, 2025

Press Release: Bionano Reports Third Quarter 2025 Results and Highlights Recent Business Progress

Dow Jones
·
Nov 14, 2025

Bionano Announces Publication Showing OGM Can Overcome Key Limitations of Targeted RNA-Seq for Cytogenetic Investigation in Acute Leukemia

GlobeNewswire
·
Nov 06, 2025

Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates

GlobeNewswire
·
Nov 06, 2025

HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event

GlobeNewswire
·
Nov 03, 2025

IT Tech Packaging Inc. held annual shareholder meeting

Reuters
·
Nov 01, 2025

argenx Reports Third Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire
·
Oct 30, 2025

Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials

GlobeNewswire
·
Oct 29, 2025

Novartis delivers solid sales and core operating income growth with strong pipeline progress in Q3; reaffirms FY 2025 guidance

GlobeNewswire
·
Oct 28, 2025

Climb Bio’s Promising ITP Study: A Potential Game-Changer for Investors

TIPRANKS
·
Oct 28, 2025